Seek news on
InfoAnda
powered by
Google
Custom Search

Last text search :
2016 wso 2.5 rw-r
2017 #1 smp wso rw-r

wso-drwxr-xr-x-smp.php-(writeable).php
2017 #1 smp wso rw-r
wso-drwxr-xr-x-smp.php-(writeable).php
wso-drwxr-xr-x-smp.php-(writeable).php
wso-drwxr-xr-x-smp.php-(writeable).php


Tuesday, 13 March 2012 - Analysis: India cancer ruling opens door for cheaper drugs |
  • Pakistanis angry over detentions in Times Sq. case
    Monday, May 24, 2010
    ISLAMABAD – Relatives of three men detained by Pakistan for alleged links to the suspect in the attempted Times Square bombing say the men are innocent.
    They
  • Taiwan denies boycotting Australian film festival
    Thursday, August 6, 2009

    AFP - Thursday, August 6TAIPEI (AFP) - - Taiwan's Beijing-friendly government on Wednesday denied boycotting an Australian film festival amid a row over the e
  • Merkel's support dips, regional ally resigns International
    Thursday, September 3, 2009

    By Sarah Marsh and Noah Barkin

    BERLIN (Reuters) - Chancellor Angela Merkel suffered a double blow on Thursday as a senior party ally in east German
  • Minister seeks closure of anti-Berlusconi websites
    Wednesday, December 16, 2009
    ROME (AFP) - – The Italian government moved Tuesday to close down Internet sites encouraging further violence against Prime Minister Silvio Berlusconi, who
  • Asian markets mixed after Wall Street rally
    Wednesday, March 18, 2009

    By ELAINE KURTENBACH,AP Business Writer AP - Wednesday, March 18SHANGHAI - Asia's stock market rally seemed to be running out of steam Wednesday, despite an
  • Row Down Under: Australia Day or Invasion Day? | 27 January 2009
  • Chinese firm suspected in missile-linked sale to North Korea: U.S. official | | 22 April 2012
  • Microsoft to pay VirnetX 200 million dollars in patent case | 18 May 2010
  • Five Iraqi policemen killed in bomb blast | | 22 February 2010


    Forum Views () Forum Replies ()

    Read more with google mobile : Analysis: India cancer ruling opens door for cheaper drugs |

      Edition: U.S. Africa Arabic Argentina Brazil Canada China France Germany India Italy Japan Latin America Mexico Russia Spain United Kingdom Home Business Business Home Economy Technology Media Small Business Legal Deals Earnings Social Pulse Business Video The Freeland File Markets Markets Home U.S. Markets European Markets Asian Markets Global Market Data Indices M&A Stocks Bonds Currencies Commodities Futures Funds peHUB World World Home U.S. Brazil China Euro Zone Japan Mexico Russia India Insight World Video Reuters Investigates Decoder Politics Politics Home Election 2012 Issues 2012 Candidates 2012 Tales from the Trail Political Punchlines Supreme Court Politics Video Tech Technology Home MediaFile Science Tech Video Tech Tonic Social Pulse Opinion Opinion Home Chrystia Freeland John Lloyd Felix Salmon Jack Shafer David Rohde Bernd Debusmann Nader Mousavizadeh Lucy P. Marcus David Cay Johnston Bethany McLean Edward Hadas Hugo Dixon Ian Bremmer Mohamed El-Erian Lawrence Summers Susan Glasser The Great Debate Steven Brill Jack & Suzy Welch Breakingviews Equities Credit Private Equity M&A Macro & Markets Politics Breakingviews Video Money Money Home Tax Break Lipper Awards 2012 Global Investing MuniLand Unstructured Finance Linda Stern Mark Miller John Wasik James Saft Analyst Research Alerts Watchlist Portfolio Stock Screener Fund Screener Personal Finance Video Money Clip Investing 201 Life Health Sports Arts Faithworld Business Traveler Entertainment Oddly Enough Lifestyle Video Pictures Pictures Home Reuters Photographers Full Focus Video Reuters TV Reuters News Article Comments (0) Slideshow Full Focus Editor's choice Our best photos from the last 24 hours.   Full Article  Images of February Follow Reuters Facebook Twitter RSS YouTube Read Afghan government team attacked, Taliban fume over massacre | 11:53am EDT UPDATE 4-Obama defends energy policies amid gas price pain 12 Mar 2012 Yahoo sues Facebook for infringing 10 patents 12 Mar 2012 Ex-Murdoch editor Brooks arrested again over hacking 11:27am EDT Republicans in three-way battle in Deep South | 12 Mar 2012 Discussed 175 U.S. serviceman detained in Afghanistan over civilian casualties 137 Israel asks U.S. for arms that could aid Iran strike 124 Sixteen Afghan civilians killed in rogue U.S. attack Watched K-Pop makes history in South America Mon, Mar 12 2012 Israeli army releases video of airstrike Sat, Mar 10 2012 Japan's year of struggle, in 60 seconds Fri, Mar 9 2012 Analysis: India cancer ruling opens door for cheaper drugs Tweet Share this Email Print Related News Pfizer scraps insulin deal with India's Biocon 10:30am EDT German stocks - Factors to watch on March 13 3:08am EDT Pfizer says Europe undermining drug innovation Mon, Mar 12 2012 Indian stocks to watch-March 13 Mon, Mar 12 2012 UPDATE 1-Bayer loses landmark Indian drug case over Nexavar Mon, Mar 12 2012 Analysis & Opinion Beneath the radar, a Russia-Pakistan entente takes shape Is the outraged Indian over-sensitive or culturally prudent? Related Topics World » Health » 1 of 3. A pharmocologist checks the toxic reaction on a swiss albino inside the bio safety cabinet at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. Credit: Reuters/Krishnendu Halder By Kaustubh Kulkarni and Henry Foy MUMBAI | Tue Mar 13, 2012 11:50am EDT MUMBAI (Reuters) - India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. It is only the second time a nation has issued a compulsory license for a cancer drug after Thailand did so on four drugs between 2006 and 2008, also on affordability grounds. Thailand also issued licenses for HIV/AIDS and heart disease treatments. "This could well be the first of many compulsory rulings here," said Gopakumar G. Nair, head of patent law firm Gopakumar Nair Associates and former president of the Indian Drug Manufacturers' Association. "Global pharmaceutical manufacturers are likely to be worried as a result ... given that the wording in India's Patent Act that had been amended from 'reasonably priced' to 'reasonably affordable priced' has come into play now." The new wording is seen as a lower threshold for compulsory licenses, which can be issued under world trade rules by nations that deem major life-saving drugs to be too costly. The licenses allow them to authorize the local manufacture or importation of much cheaper, generic versions. Global drugmakers see emerging markets such as India as key growth opportunities, but remain concerned over intellectual property protection. Nair said HIV-related medicines were likely to be the most at risk by compulsory licenses in the future. India has one of the world's fastest-growing rates of HIV and heart disease is also the country's biggest killer, but widespread poverty in Asia's third-largest economy makes many non-generic drugs unaffordable for millions. Currently, Pfizer and GlaxoSmithKline sell a modern HIV/AIDS drug known as Selzentry through their joint venture firm ViiV Healthcare. The treatment costs more than 60,000 rupees ($1,200) for one month's dosage in India. Bayer's Nexavar cancer drug costs around $5,500 a month in India, making it "not available to the public at a reasonably affordable price", the patent office ruled. About 40 percent of Indians live below the poverty line, government data shows. A provision of the Indian Patents Act allows for a compulsory license to be awarded after three years of the grant of patent on drugs that are deemed to be too costly. MORE TO COME? Other patent rulings are imminent. A long-running case involving the granting of an Indian patent for Swiss drugmaker Novartis' cancer drug Glivec is expected to be heard in the country's Supreme Court this month. The case does not involve the issue of compulsory license, but it has also pitted advocates of free trade and intellectual property rights against pro-generics campaigners who say a ruling in favor of Novartis could see other drugs in India priced outside of the reach of most of the population. "This (Bayer) case might become a trend-setter, wherein generic players can make copies of patented products," said Siddhant Khandekar, analyst at ICICI Direct. "While global giants might not like this, generic companies will benefit along with common people," he said, adding that the cancer treatment market in India was worth up to 30 billion rupees ($600 million). The Bayer case underscores the still fractious relationship between global pharmaceutical firms and India. Companies like Pfizer, GlaxoSmithKline and Novartis are eyeing India and other emerging markets, notably China, as a growth opportunity but worry about property protection in a country that is also a leading source of cheap copycat medicines. "Big Pharma" has recently struck some alliances with Indian drugmakers to tap into their generics expertise, but these have also not always run smoothly, with Pfizer on Tuesday scrapping a partnership with India's Biocon Ltd. In cancer treatments, India's Cipla Ltd, which has the second largest share of the local drugs market, may also benefit from the Bayer case. Cipla is fighting a Bayer suit for patent infringement after the Indian drugmaker launched a generic version of Nexavar in India in April 2010. BAYER CONSIDERS OPTIONS Natco's finance chief, Baskara Narayana, told Reuters that sales of the generic version of Nexavar, whose chemical name is sorafenib, were expected to be about 250 million to 300 million rupees ($5-6 million) a year once it is launched. Bayer, which developed Nexavar with U.S. biotech firm Onyx Pharmaceuticals, said it was evaluating its options. "We are disappointed by the decision of the Patent Controller in India to grant a compulsory license for Nexavar," Bayer said in a statement. Tapan Ray, director general of the Organization of Pharmaceutical Producers of India, an industry group of multi-national drugmakers, said the Bayer ruling was disappointing. "The solution to helping patients with innovative medicines does not lie in breaking patents or denying patent rights to the innovators," Ray said. Pfizer has questioned the issue of affordability, saying many Indians are well off and can afford Western medicines. "There is huge wealth in India," Pfizer CEO Ian Read told Reuters in London on Monday. "There are maybe 100 million people in India who have wealth equivalent to or greater than the average European or American, who don't pay for innovation. So this is going to have to be a discussion at some point." But groups that campaign for cheap access to drugs in poor countries have welcomed the Bayer ruling. Medecins Sans Frontieres said the ruling means that new medicines in India that are still under patent, including some of the latest treatments for HIV/AIDS, could potentially have generic versions produced for a fraction of the cost. "It's a bold move by the government and it's a good judgment ... which will benefit people," said Dara Patel, secretary general of the Indian Drug Manufacturers' Association, an industry body of Indian companies. "Drugs to treat heart-related diseases and HIV are costly," said Patel. "Compulsory licensing will make them available at one-fourth or one-fifth of the price, which is good." ($1 = 49.9750 Indian rupees) (Additional reporting by Ben Hirschler in LONDON and Tan Ee Lyn in HONG KONG; Editing by Tony Munroe and Mark Bendeich) World Health Related Quotes and News Company Price Related News Tweet this Link this Share this Digg this Email Reprints   We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/ Comments (0) Be the first to comment on reuters.com. Add yours using the box above.   Edition: U.S. Africa Arabic Argentina Brazil Canada China France Germany India Italy Japan Latin America Mexico Russia Spain United Kingdom Back to top Reuters.com Business Markets World Politics Technology Opinion Money Pictures Videos Site Index Legal Bankruptcy Law California Legal New York Legal Securities Law Support & Contact Support Corrections Advertise With Us Connect with Reuters Twitter   Facebook   LinkedIn   RSS   Podcast   Newsletters   Mobile About Privacy Policy Terms of Use Copyright Our Flagship financial information platform incorporating Reuters Insider An ultra-low latency infrastructure for electronic trading and data distribution A connected approach to governance, risk and compliance Our next generation legal research platform Our global tax workstation Thomsonreuters.com About Thomson Reuters Investor Relations Careers Contact Us   Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests. NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

    Other News on Tuesday, 13 March 2012
    Iran executed 670 in 2011, says U.N. investigator |
    In spotlight, Uganda says Congo slows hunt for Kony |
    Turkey court releases journalists in conspiracy case |
    Putin critics say U.S. should open trade with Russia |
    Yahoo sues Facebook for infringing 10 patents |
    Youku to buy Tudou, creating China online video giant |
    Diller-backed Aereo countersues broadcasters |
    Infosys CEO says has 'pretty strong' order pipeline |
    Batman brings order to southern Slovak town |
    Massacre makes Obama more determined to leave Afghanistan |
    Israel, Gaza militants agree to truce: Egypt official |
    Majority of Japanese oppose nuclear plant restarts: poll |
    Suicide bomber kills three Yemeni soldiers-police source |
    Pakistani U.N. peacekeepers sentenced in Haiti rape case |
    Iran executed 670 in 2011, says U.N. investigator |
    Insight: How German history helps modern spies |
    Exclusive: France's Le Pen clears hurdle to stand in election |
    Over 150 passengers missing as ferry sinks in Bangladesh |
    Yahoo sues Facebook for infringing 10 patents |
    Apple, Motorola held cross-licensing talks late 2011: EU |
    Beijing takes a brand-new approach to Made in China |
    Twitter acquires Posterous |
    Intel eyes Internet-based TV service: WSJ |
    MTV Europe Music Awards return to Frankfurt in 2012 |
    French actor confirms engagement to Halle Berry: report |
    Whitney Houston's daughter hears mom talk to her |
    Violence across Syria; U.N. awaits response from Damascus |
    U.S. drone strikes kill 15 in northwest Pakistan |
    Turkish police fire teargas after controversial court ruling |
    Analysis: India cancer ruling opens door for cheaper drugs |
    Sudan rebels say they shot down drone, government denies |
    Belgian mosque attacked with petrol bomb, one dead |
    No display shortage seen for new iPad: Jefferies |
    Hynix says chip supply requests jump on Elpida troubles |
    iPads may boost residents' efficiency: study |
    With film music, Brussels orchestra veers from usual business model |
    Salman Rushdie to return to India after death threats |
    Greece at new risk of being pushed off euro
    Bodies of missing Tenn. mom, Jo Ann Bain, and daughter found
    Female Breasts Are Bigger Than Ever
    AMD Trinity Accelerated Processing Units Now in Volume Production
    The Avengers (2012 film), made the second biggest opening- and single-day gross of all-time
    AMD to Start Production of piledriver
    Ivy Bridge Quad-Core, Four-Thread Desktop CPUs
    Islamists Protest Lady Gaga's Concert in Indonesia
    Japan Successfully Broadcasts an 8K Signal Over the Air
    ECB boosts loans to 1 trillion Euro to stop credit crunch
    Egypt : Mohammed Morsi won with 52 percent
    What do you call 100,000 Frenchmen with their hands up
    AMD Launches AMD Embedded R-Series APU Platform
    Fed Should not Ignore Emerging Market Crisis
    Fed casts shadow over India, emerging markets
    Why are Chinese tourists so rude? A few insights

    [InfoAnda] [Home] [This News]



    USD EUR - 1 year graph

    VPN on MacOSX

    BlogMeter 1.01